Skip to Content

Disclaimer

Disclaimer
MDS makes every effort to publish accurate information on the website. "Google Translate" is provided as a free tool for visitors to read content in one's native language. Translations are not guaranteed to be 100% accurate. Neither MDS nor its employees assume liability for erroneous translations of website content.

International Parkinson and Movement Disorder Society
Main Content

        VOLUME 29, ISSUE 1 • MARCH 2025.  Full issue »

2nd LARGE-PD meeting organizes leaders toward tangible next steps


Peruvian warmth, rich history, and the vibrant city of Lima set the stage for the Second Annual Meeting of Researchers of the Latin American Research Consortium on the Genetics of Parkinson’s Disease (LARGE-PD) on November 28-30,2024, bringing together over 80 participants from 33 sites in 14 Latin American countries to reinforce the consortium’s commitment to advancing Parkinson’s disease (PD) research in the region.  

While the First Annual LARGE-PD Meeting in Cali, Colombia, focused on establishing the foundation of the consortium and learning about each site’s capabilities, the second meeting in Lima marked a significant evolution. Discussions centered on presenting concrete research findings through a poster session, reviewing ongoing and future projects, and forming dedicated working groups that will enable more efficient collaboration in different aspects of PD. 

The meeting addressed key aspects of research on the genetics of PD in Latin America, including ancestry composition, protocol and IRB approvals, budget execution, recruitment strategies, applied questionnaires, sample management harmonization, return of genetic results to participants, and training opportunities. 

A crucial topic discussed during the meeting was the implementation and expansion of the PD GENEration program within the LARGE-PD consortium, in collaboration with the Parkinson’s Foundation. This initiative aims to provide CLIA-certified genetic testing for seven PD-related genes (LRRK2, GBA, SNCA, PRKN, PINK1, DJ-1, VPS35) at no cost to participants, ensuring that individuals receive their results through appropriate genetic counseling sessions to facilitate understanding and informed decision-making. 

In 2024, a pilot program was successfully conducted at selected LARGE-PD sites, yielding very promising results in terms of participant engagement, feasibility, and impact on clinical decision-making. The success of this pilot phase, with almost 700 participants recruited in less than 8 months, underscored the critical need for accessible genetic testing across Latin America, paving the way for a region-wide expansion of PD GENEration. Now, in 2025, the program is entering a new phase, with plans to expand across all LARGE-PD sites in Latin America. 

Another highlight was the working groups session, where researchers with shared interests collaborated on specific themes relevant to the consortium. The discussions from these sessions set the foundation for specialized research efforts moving forward. 

Themes of the Large-PD working groups sessions

  • Cognition in Parkinson's Disease

  • Atypical parkinsonism  

  • PD GENEration

  • Neuroimaging 

  • Monogenic Parkinson´s disease 

  • Biobank and protocol harmonization  

The meeting provided an ideal setting for dynamic discussions and meaningful collaborations. Thanks to the efforts of the organizing team at the Universidad Cientifica del Sur, the Instituto Nacional de Ciencias Neurológicas in Lima, Peru, and the support of the core LARGE-PD team at the Cleveland Clinic in Ohio, USA, the event strengthened the consortium’s collaborative network and established clear strategies for the future of LARGE-PD. Special thanks to GP2/ASAP, Michael J. Fox Foundation, and Parkinson's Foundation for their invaluable support, as well as the meeting faculty, researchers, attendees for dedicating their time to share experiences and advance the study of PD genetics in Latin America. 

 

 

Read more Moving Along:

Full issue    Archives

We use cookies to give you the best possible experience with our website. These cookies are also used to ensure we show you content that is relevant to you. If you continue without changing your settings, you are agreeing to our use of cookies to improve your user experience. You can click the cookie settings link on our website to change your cookie settings at any time. Note: The MDS site uses related multiple domains, including mds.movementdisorders.org and mds.execinc.com. This cookie policy only covers the primary movementdisorders.org and mdscongress.org domain. Please refer to the MDS Privacy Policy for information on how to configure cookies for all other domains on the MDS site.
Cookie PolicyPrivacy Notice